[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625310":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":18,"responsibleParty":40,"collaborators":42,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":18,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":18,"enrollmentInfo":55,"targetDuration":18,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":69,"whyStopped":18,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":18},{"fullName":5,"class":6},"Medstar Health Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Continuation of insulin pump therapy intrapartum","EXPERIMENTAL","Patients with type 1 or 2 diabetes already on insulin pump therapy for at least 2 months with continued utilization of insulin pump for blood glucose management while in labor (intrapartum)",[13],"Device: Insulin pump",{"label":15,"type":16,"description":17,"interventionNames":18},"Retrospective historic cohort with standard care (intravenous insulin drip) intrapartum","NO_INTERVENTION","Retrospective historic cohort of patients with type 1 or 2 diabetes with antenatal use of insulin pump, managed with standard care (discontinuation of insulin pump and transition to intravenous insulin drip) in labor (intrapartum)",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Insulin pump","Intrapartum continuation of insulin pump therapy",[9],[26],"Hybrid closed loop automated insulin delivery (AID) system",[28],{"name":29,"affiliation":30,"role":31},"Victoria Greenberg, MD","MedStar Health","PRINCIPAL_INVESTIGATOR",[33,37],{"name":29,"role":34,"phone":35,"phoneExt":18,"email":36},"CONTACT","301-782-3353","victoria.r.greenberg@medstar.net",{"name":38,"role":34,"phone":18,"phoneExt":18,"email":39},"Elizabeth Miller, MD","elizabeth.miller@medstar.net",{"type":41,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[43],{"name":44,"class":45},"Latham Fund","UNKNOWN","100625310","pilot-study-of-intrapartum-insulin-pump-100625310",false,"NCT07420972","Pilot Study of Intrapartum Insulin Pump","Pilot Study of Intrapartum Insulin Pump Use: Feasibility, Efficacy and Safety","Inclusion Criteria:\n\n* Singleton gestation\n* Established Type 1 or 2 diabetes mellitus\n* Use of continuous subcutaneous insulin infusion for ≥2 months prior to delivery, -Demonstrated cognitive ability to self-manage insulin, familiarity with pump technology, availability of necessary supplies, stable clinical status\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Planned cesarean delivery without labor\n* Significant comorbidities affecting insulin requirements (e.g., steroid therapy)\n* Stillbirth prior to presenting for delivery\n* Known severe fetal anomalies.","FEMALE","18 Years",{"count":56,"type":57},30,"ESTIMATED","INTERVENTIONAL",[60],"NA","People with type 1 or type 2 diabetes often use insulin pumps to manage their blood sugar during pregnancy. These pumps can help keep blood sugar in a healthy range. However, when people come to the hospital to give birth, they are often asked to stop using their insulin pump and switch to insulin given through an IV. This change can be stressful and may make blood sugar harder to control during labor. There is not enough research to know if it is safe and practical for people to keep using their insulin pump while in labor.\n\nThe goal of this study is to learn whether it is safe, practical, and acceptable for pregnant people with diabetes to continue using their insulin pump during labor. The study will also look at how this approach compares to standard care, which uses IV insulin.\n\nThis is a small pilot study. About 30 pregnant people with type 1 or type 2 diabetes will take part. All participants already use an insulin pump and receive care through the MedStar Diabetes in Pregnancy Program. Participants will be allowed to continue using their own insulin pump during labor, following a hospital safety plan. Their outcomes will be compared to similar patients from the past who used IV insulin during labor.\n\nThe main focus of the study is to see how often people can safely stay on their insulin pump during labor and how well this approach fits into hospital care. The study will also collect information about blood sugar levels during labor and health outcomes for newborns, such as low blood sugar, breathing problems, or need for care in the neonatal intensive care unit. These outcomes are being studied to help plan future research.\n\nAfter delivery, participants will be asked to share their experience. This includes how satisfied they were with their diabetes care during labor, how much control they felt over their care, and how difficult or easy the treatment was to manage. Nurses and doctors will also provide feedback about caring for patients who use insulin pumps during labor.\n\nParticipants will continue to check their blood sugar using continuous glucose monitoring, with fingerstick checks when needed. If any safety concerns arise, such as blood sugar levels that are too high or too low, participants will switch to standard IV insulin.\n\nThis study is not meant to prove that one method is better than another. Instead, it will help researchers decide whether a larger study should be done in the future. The long-term goal is to improve diabetes care during labor and support safe, patient-centered options for people with diabetes and their babies.",[63,64,65],"Diabetes","Diabetes (Insulin-requiring, Type 1 or Type 2)","Pregnancy",[22,63,67,68,65],"Type 1 diabetes","Labor","NOT_YET_RECRUITING","2026-02-11",{"date":72,"type":73},"2026-02-19","ACTUAL",{"date":75,"type":57},"2026-04",{"date":77,"type":57},"2028-04",{"name":5,"class":6}]